Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.

Company Growth (employees)
Utrecht, NL
Size (employees)
67 (est)+9%
Merus was founded in 2003 and is headquartered in Utrecht, NL

Merus Office Locations

Merus has an office in Utrecht
Utrecht, NL (HQ)
H.R. Kruytgebouw 8 Padualaan

Merus Data and Metrics

Summary Metrics

Merus's latest funding round in April 2015 was reported to be $79.1 m. In total, Merus has raised $149.3 m

Traffic Overview of Merus

Merus News and Updates

BRIEF-Merus announces Q1 loss per share EUR 0.63

* Merus announces first quarter 2016 financial results and highlights recent clinical progress and corporate developments

BRIEF-Merus says pound depreciation to marginally impact EBITDA

* Merus announces reduced leverage and provides business update

Merus Company Life and Culture

You may also be interested in